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Abstract
Liquid biopsy testing is a new laboratory-based method that detects tumour mutations in circulating free DNA (cfDNA)
derived from minimally invasive blood sampling techniques. Recognising the significance for clinical testing, in 2017,
IQN Path provided external quality assessment for liquid biopsy testing. Representatives of those participating laboratories
were invited to attend a workshop to discuss the findings and how to achieve quality implementation of cfDNA testing in
the clinical setting, the discussion and outcomes of this consensus meeting are described below. Predictive molecular
profiling using tumour tissue in order to select cancer patients eligible for targeted therapy is now routine in diagnostic
pathology. If insufficient tumour tissue material is available, in some circumstances, recent European Medicines Agency
(EMA) guidance recommends mutation testing with plasma cfDNA. Clinical applications of cfDNA include treatment
selection based on clinically relevant mutations derived from pre-treatment samples and the detection of resistant muta-
tions upon progression of the disease. In order to identify tumour-related mutations in amongst other nucleic acid material
found in plasma samples, highly sensitive laboratory methods are needed. In the workshop, we discussed the variable
approaches taken with regard to cfDNA extraction methods, the tests, and considered the impact of false-negative test
results. We explored the lack of standardisation of complex testing procedures ranging from plasma collection, transport,
processing and storage, cfDNA extraction, and mutation analysis, to interpretation and reporting of results. We will also
address the current status of clinical validation and clinical utility, and its use in current diagnosis. This workshop revealed
a need for guidelines on with standardised procedures for clinical cfDNA testing and reporting, and a requirement for
cfDNA-based external quality assessment programs.
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Introduction
The National Cancer Institute defines liquid biopsy as a test
performed on blood samples in order to look for cancer cells
from a tumour that are circulating in the blood, or for pieces of
DNA from tumour cells that are in the blood [1]. Being a non-
invasive, cost-effective procedure, which rapidly detects and
monitors molecular biomarkers in cancer patients, analysis of
plasma cfDNA testing has shown great promise to become a
useful clinical tool. It is particularly useful in identifying
targeted treatments and monitoring tumour response to
therapy.
However, plasma cfDNA testing is not without challenges:
establishment of optimal timings between blood draw and
blood processing, optimising DNA extraction procedures,
identifying appropriate analysis methods and ensuring accu-
rate interpretation of results. With these issues in mind, IQN
Path, a network of quality assessment experts with an interest
in cancer biomarker testing, collected data on liquid biopsy
testing in Europe in 2017 [2] provided an external quality
assessment [3] and organised a cfDNAworkshop which was
attended by European key opinion leaders. The purpose of the
workshop was to summarise the current limited knowledge on
liquid biopsy testing and to establish a white paper to empha-
sise the need for standardisation of the implementation cfDNA
testing in clinical practice. This article summarises the work-
shop discussions.
Current applications of cfDNA mutation
testing
The current clinical applications of cfDNA mutation testing
are the identification targeted therapies in non-small cell lung
cancer (NSCLC) by testing for epidermal growth factor recep-
tor (EGFR) mutations, and the assessment of Kirsten RAt
Sarcoma (KRAS), Neuroblastoma RAS viral oncogene homo-
logue (NRAS) and v-Raf murine sarcoma viral oncogene ho-
mologue B (BRAF)mutation status in patients with colorectal
cancer (CRC), in situations when molecular testing is not fea-
sible on tissue due to insufficient/inadequate material or in-
ability to perform a biopsy [4]. Clinical trials have shown that
analysis of serial cfDNA samples during cancer treatment can
monitor tumour response and identify early emergence of any
resistance mechanisms [5–8]. Following targeted therapy,
cfDNA testing can identify treatment-resistant mutations. In
the event that cfDNA plasma testing does not detect a muta-
tion, a solid tumour tissue biopsy and the cfDNA plasma test
should be conducted concurrently, as the results may help
inform recommendations for novel treatment options.
Different tumour types raise their own particular issues [9].
For example, in patients with NSCLC who have brain metas-
tases or intra-thoracic disease, the chances of detecting cfDNA
mutations in plasma are reduced [10]. In patients with gastro-
intestinal stromal tumours (GIST), targetableKITmutations in
pre-treatment tumour biopsies are not detected in one in nine
patients with localised or local advanced disease, whereas in
13 of 14 cases with metastasized advanced GIST, KIT muta-
tions are detected in pre-treatment plasma [6]. In patients with
CRC [7, 11–13] and with NSCLC regarding the detection of
resistance mutations upon progression on tyrosine kinase in-
hibitors [14, 15], a key issue is the sensitivity of the different
assays.
Today, the clinical utility of cfDNA testing that is re-
quired to evaluate whether clinical outcome for patients
who were treated based on the test has improved compared
to those not tested, and has not been performed for most
tumour types despite major achievements regarding analyt-
ical validity and clinical validity [16, 17]. Therefore,
cfDNA testing is not appropriate for diagnosis (without
tissue diagnosis). The only two FDA-approved cfDNA-
based tests with clinical utility are the cobas EGFR
Mutation Test v2 (Roche Diagnostics) detecting EGFR
mutations in cfDNA from patients with lung cancer [3,
18] and the Epi proColon assay (Epigenomics AG) for
the detection of SEPT9 promoter methylation in cfDNA
from patients undergoing screening for CRC [19].
However, the expectations of the clinical applications of
cfDNA testing are high. If implemented well, performed at
high quality (according to ISO 15189) [20], it can be a reli-
able, robust, reproducible, cost-effective and accurate test with
a fast turn-around time. It is anticipated that in the future, a
trend towards multiplexed and quantitative cfDNA testing
methods as these will yield even larger amounts of useful
clinical information.
Sample collection and processing
The volume of blood required for cfDNA analysis is de-
pendent upon the testing methodology but generally ranges
between 6 and 10 ml. Clearly, handling of blood samples
impact on the quality of the cfDNA testing and on the
downstream results and tubes should be spun and proc-
essed as soon as possible. Therefore, tubes selected for
blood collection must be appropriate to maintain the integ-
rity of the sample, taking into consideration the time be-
tween the blood draw and laboratory processing, the avail-
ability of any storage facilities and the mechanism of trans-
port to the processing laboratory. Current methods typical-
ly involve blood collection in EDTA anti-coagulant tubes,
storage at 4 °C, and transportation to the pathology labo-
ratory where the sample is processed and stored at −80 °C,
all within a timeframe of 6 h. However, these options are
not always feasible; therefore, the use of tubes containing
preservatives to prevent haemolysis and to reduce the
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degradation of cfDNA is becoming increasingly common
practice to allow an extended period of time before blood
must be processed. Laboratories must apply acceptance
criteria to ensure that received samples are suitable for
cfDNA mutation testing. Processing protocols should en-
tail a double centrifugation protocol, including initial slow
centrifugation, with the eluted plasma subjected to a sec-
ond fast centrifugation. The resultant plasma layer can be
used for cfDNA extraction immediately or can be stored
either at − 20 °C for fewer than 5 days or at − 80 °C for
longer storage. Freeze thawing sample aliquots is not rec-
ommended. Table 1 summarises the advantages and disad-
vantages of current options.
DNA extraction
Plasma samples can contain a variable amount of high molec-
ular weight (HMW) DNA as a result of haemolysis during
processing. In contrast, plasma ctDNA (circulating tumour)
fragments have an average size of 132–1450 base pairs (bp)
corresponding to mononucleosome-protected DNA [17, 21].
With growing interest in cfDNA-based diagnostics, a number
of cfDNA-focused extraction kits are available from various
manufacturers (Table 2). However, none of the current cfDNA
extraction methodologies enrich either ctDNA or the
nucleosome-protected DNA fragments. Studies comparing
cfDNA extraction methods and kits revealed large differences
in total DNA yield [22–24]. These findings may be due to a
variety of reasons, including variations in extraction method-
ology, plasma input and elution volume, or that with low vol-
umes of available plasma cfDNA, there is a tendency to load
larger plasma volumes and elute the cfDNA fragment with the
lowest volume to maximise concentration. So, to select the
optimal cfDNA extraction kit, factors such as the extraction
method, time, throughput and price should be considered.
To compare the performance of different cfDNA extraction
methods, most studies focus on cfDNAyield, quantifying the
yield with techniques such as fluorospectroscopy, fluorometry
and quantitative real-time PCR (qPCR). In general, quantifi-
cation of DNA elutes shows a significant correlation with
qPCR [23], while non-double-stranded DNA measurement
assays do not.
High levels of nucleosome-protected DNA from non-
tumour tissues in addition to HMW DNA can complicate
ctDNA molecular analysis by increasing the rate of false-neg-
atives. Hence, the integrity of any extracted cfDNA should be
tested. However, typical methods that measure cfDNA quan-
tity do not assess extracted DNA integrity. Integrity testing
options include fragment analysis which employs capillary
electrophoresis to determine DNA fragment length: The size
of DNA fragments is used to evaluate the relative amount of
nucleosome-protected 140–160 bp DNA fragments compared
to HMWDNA and DNA degradation [22, 23]. More recently,
amplifiable DNA concentrations and the fragment size have
beenmeasured using very small amounts of cfDNA in various
single-tube multiplex digital droplet PCR (ddPCR) assays [6,
25, 26].
So, in the case of insufficient cfDNA, the cfDNA should be
quantified using a double-stranded DNA method before pro-
ceeding to PCR or sequencing analysis. In addition, as various
factors can complicate the molecular analysis of cfDNA, the
integrity of any extracted cfDNA should be estimated. Finally,
the amount of ctDNA can not only be influenced by pre-
analytical procedures such as haemolysis, centrifugation and
cfDNA extraction procedures, but it has been reported that
ctDNA levels differ significantly between various tumour
types, stages of disease, tumour volume and stages of
Table 1 Summary of the advantages and disadvantages of available
blood collection tubes
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treatment [6, 9]. Different levels of total cfDNA are also in-
fluenced upon extreme exercise, infectious disease and age
[27]. In short, we should realise that today, the dynamics of
the release of DNA from cancer cells into the circulation, the
mechanism of clearance as well as half-life of cfDNA, are still
poorly understood.
Testing methods
Plasma often contains very low levels of cfDNA; therefore,
methods are needed, different from those used for targeted
detection of defined oncogenic variants in tissue biopsy, with
a very high analytical sensitivity (0.01–0.1%). Assays for the
detection of the same variants in cfDNA include amplified
refractory mutation system (ARMS), allele-specific quantita-
tive PCR, PCR with peptide nucleic acid clamps, next-
generation sequencing (NGS), BEAMing and ddPCR [5, 17,
28, 29]. These assays should be optimised for sensitivity in
order to detect cfDNAwhich may be present in lower concen-
trations than DNA isolated from cancer tissue [30]. Many
laboratories have focused on improving cfDNA assay speci-
ficity, in order to make it more useful as a screening tool. A
meta-analysis of 20 studies demonstrated that specificities
achieved using cfDNA were comparable to solid tissue
genotyping [31]. The performance of NGS, which enables
broader gene profiling, has also been evaluated using
cfDNA with some studies showing similar sensitivities and
specificities when compared to single-gene assays [32–35].
In contrast, an international pilot External Quality
Assessment (EQA) scheme observed a higher method-
specific error rate for NGS compared to ddPCR and commer-
cial kits [3].
The choice of assay will depend on multiple factors includ-
ing clinical requirements, throughput, specificity, sensitivity,
and access to equipment, expertise and budget. Table 3 sum-
marises some of the commonly used assays for detecting
clinical-relevant EGFR variants in cfDNA derived from
NSCLC. The clinical oncology demand for testing of variants
other than EGFR will help establish multigene testing as rou-
tine practise in future.
Reporting results
Reporting the results of plasma cfDNA mutation testing
should follow standard guidelines for reporting of molecular
pathology results [36, 37] and adhere to the ISO15189 stan-
dard for medical laboratories [20]. Reports should be clear and
concise within a maximum of two pages. It should be clearly
stated that cfDNA testing has been performed and include two
patient-specific identifiers, a sample identifier and the sample
type tested. Pagination should be used and included with the
date and time of sampling, a clear statement of the results,
details of the testing method performed, limitations of the test
including sensitivity of the assay, reason for referral, appropri-
ate interpretation of results and details of the reporter and
authoriser. Genotyping results should be given according to
Human Genome Variation Society (HGVS) nomenclature
Table 2 Examples of currently
available cfDNA extraction
methods
cfDNA extraction kit Manufacturer
QIAamp® circulating Nucleic Acid Kit Qiagen
QIAamp® DNA Blood Mini Kit Qiagen
EZ1® ccfDNA Kit Qiagen
QIAsymphony PAXgene Blood ccfDNA Kit Qiagen
QIAsymphony DSP Circulating DNA Kit Qiagen
QIAamp® MinElute® ccfDNA Qiagen
cfDNA isolatie van Quick-cfDNA™ Serum and Plasma DNA Miniprep Kit Zymo Research
Maxwell® RSC ccf Plasma Kit Promega
Cobas® cfDNA Sample Preparation Kit Roche Diagnostics
NucleoSpin® Kit Macherey-Nagel
MagNA Pure Isolation System Roche Diagnostics
Plasma ccf DNA purification kit Norgen BioTek
Chemagic cfDNA isolation kit Perkin-Elmer
FitAmp Plasma/Serum DNA isolation kit Epigentek
PME free circulating DNA extraction KIT Analytik Jena
EpiQuick™ cfDNA Isolation Easy Kit Epigentek
NEXTprep-Mag™ cfDNA Kit Bio Scientific/PerkinElmer
Idylla™ ctKRAS Plasma Test (DNA extraction is part of detection-test) Biocartis
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[38], and the predicted protein change should be presented
with appropriate reference sequences.
Further details may be included if it pertains to the result,
for example, the tube type used for blood collection or if there
is evidence of haemolysis. These details should be noted with-
in the molecular testing laboratory even if not included on the
external report.
The sensitivity of the method of cfDNA analysis should
be stated. As the total amount of cfDNA will vary, it is
recommended that both the variant allele frequency
(VAF) and the amount of mutant copies per milliliter of
plasma are reported. Standardisation is encouraged to aid
result interpretation and for the comparison of data be-
tween laboratories. Ultimately, the total cfDNA prior to
the analysis of mutations and the limit of sensitivity of
the assay are useful additions to any reporting. Any previ-
ous molecular analyses should also be outlined and previ-
ously detected mutations re-stated, for subsequent analysis
may include the detection of primary mutations.
The interpretation of the molecular result depends on the
gene analysed, the tumour type and the clinical context of the
gene-drug interaction. However, the analysis of cfDNA re-
quires additional consideration, as the presence or absence
of cfDNA is unknown in the absence of a detectable mutation.
The detection of a mutation will generally lead to a simple
interpretation of the mutation present result. However, a mu-
tation absent result could be due to a variety of reasons
including:
& The mutation is not detected and is therefore a true
negative.
& Insufficient sample of ctDNA giving a possible false
negative.
& The sampling method destroyed any ctDNA giving a pos-
sible false negative.
& The analytical method is insufficiently sensitive to detect
low levels of mutant ctDNA, resulting in a false negative.
When no mutation is detected, the report should either
include a remark that Bmutation not detected does not rule
out the presence of a mutation because the analysis de-
pends on LOD of the test, and quality and quantity of the
input cfDNA^ or contain specific information on the qual-
ity control metrics of the assays regarding the LOD of the
tested sample. For example, for ddPCR, this should be
based on the number of mutant droplets in no template
controls divided by the total number of positive droplets.
A Bmutation absent^ result must be treated with caution,
and the above possibilities should be referred to, and repeat
sampling recommended, preferably by biopsy. Dependent
on the gene, tumour type and clinical context, additional
controls may be included which may aid interpretation, as
previously described.
Quality considerations
High-quality cfDNA testing procedures yield high quality re-
sults. Validation and verification of laboratory methods and
procedures ensure a safe and useful service for clinicians and
patients. However, errors in the pre-analytical phase can lead
to false-positive or false-negative results which can result in
misdiagnosis and inappropriate treatment. There are a number
of issues to consider in the establishment and maintenance of
high-quality processes.
Laboratories must have sample acceptance criteria which
are then communicated to the clinicians requesting and
collecting samples. Sample storage must be documented and
monitored, and further sample preparation procedures validat-
ed. Methods should be optimised for sensitivity and cost-ef-
fectiveness. Test development, assessment of utility and per-
formance specification should be properly documented.
Test validation should include different kinds of variants such
as point mutations or small insertions and deletions, as well as
positive and negative internal quality controls, the type of which
largely depends on the methodology used. Validation should
focus on samples that have been processed through all clinical
workflows, and critically on cfDNA samples with variants at the
limits of sensitivity. In addition, to permit the reliable detection of
rare clinically relevant variants, regular external and internal val-
idation should assess and monitor the quality of test results and,
when required, modify existing methods and procedures.
Commercially available reference standards can be used as
internal quality controls. To monitor the performance of each
test, it is recommended that samples harbouring a different
percentage of mutant allele up to the limit of detection are
used. However, it should be noted that cell line and synthetic
materials may not be optimal substitutes for ctDNA derived
from blood or plasma [39].
Laboratories are advised to optimise their workflow design
and embrace quality control parameters. To avoid contamina-
tion, different test phases should be performed in contained
compartments. Turnaround time should be closely monitored,
and action taken the clinically acceptable timeframe is
exceeded. Detailed standard operating procedures are required,
and all personnel should be adequately trained in these and kept
informed of any changes. Laboratories are encouraged to regu-
larly demonstrate that their testing procedures deliver accurate
and reliable results by implementing regular internal audits and
to participate in external quality assurance. We strongly recom-
mend that all processing steps should be performed and moni-
tored according to the requirements of ISO15189 [20].
Finally, when outsourcing any part of cfDNA analysis to an
external laboratory, the referring laboratory must be responsi-
ble for documenting procedures used for the selection and
evaluation of the external laboratory and should monitor the
quality of performance and ensure that it is competent to per-
form the required testing.
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Conclusion
It was clear from the workshop that many laboratories in
Europe already perform cfDNA testing or are planning to
adopt it for NSCLC for treatment selection and resistance
monitoring. This paper summarises the discussions about
cfDNA testing in clinical practice from the workshop and
encompasses several aspects of cfDNA mutation testing, in-
cluding technical considerations, quantity and quality of ex-
tracted cfDNA, the advantages and disadvantages of different
testing methods, reporting of results and quality assurance and
quality control. The workshop highlighted the different ap-
proaches taken by testing laboratories through the pathway,
end to end, i.e. from blood collection, cfDNA extractionmeth-
od, assays performed and reporting of the results. cfDNA
testing has the potential for broader applications in clinical
practice in the future, and we anticipate that the use of multi-
plex methods will continue to increase as larger volumes of
data can be generated from one sample that may provide ad-
ditional insights into treatment options for patients.
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